On 28 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the submission of a Phase II clinical trial application for its self-developed RBD1119 Injection to the European Medicines Agency (EMA).

RBD1119 is described as a novel small-interfering RNA (siRNA) antithrombotic therapy designed to provide effective and sustained protection against thrombosis in patients with coronary artery disease (CAD) while aiming to maintain a favorable bleeding-risk profile. The company highlighted that despite widespread use of antiplatelet and anticoagulant regimens, patients with stable CAD still face meaningful residual thrombotic risk, and intensified therapy is frequently constrained by bleeding concerns.

The voluntary disclosure underscores that RBD1119 remains under clinical development. Suzhou Ribo Life Science cautions that successful completion of development and commercialisation is not guaranteed, and advises shareholders and potential investors to exercise caution when dealing in the company’s shares.